Bloomberg
@business
The first word in business news | Watch Live: | Newsletters: | Podcasts:
加入 April 2009
104 正在关注 10.5M 粉丝
Novo Nordisk will pay as much as $2.6 billion to license an experimental obesity pill from China’s Hengrui, as it seeks to rebuild investor confidence in its future beyond blockbusters Ozempic and Wegovy
显示更多
